Interim analysis of Merck's Vytorin trial delayed

Sept 13 (Reuters) - Merck & Co said on Tuesday an interim analysis of a clinical trial of its cholesterol drug Vytorin will be delayed, though the company's chief financial officer said the delay would not affect the overall timing of its regulatory review.